DALLAS, Nov. 19, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biotechnology company Sinobiopharma Inc. (OTCBB:SNBP). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Sinobiopharma Inc. (OTCBB:SNBP) should be of particular interest to other biotechnology companies: Sunesis Pharmaceuticals Inc. (Nasdaq:SNSS), Prestige Brands Holdings Inc. (NYSE:PBH), Synta Pharmaceuticals Corp. (Nasdaq:SNTA) and GlaxoSmithKline plc (NYSE:GSK).
The full report is available at: http://www.stockpreacher.com/n/SNBP
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Sinobiopharma Inc. (SNBP) is an emerging, fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. SNBP's flagship drug -- Cisatracurium besylate -- captured 65% of the Chinese market within 14 months of launch.
Message Board Search for SNBP: http://www.boardcentral.com/boards/SNBP
In the report, the analyst notes:
"SNBP's key product is a patented version of Cisatracurium besylate, a pre-surgical skeletal muscle relaxant marketed as Kutai in China, and is the world's first that can be stored at room temperature. ... In March 2009, the Company announced that its patented version of Cisatracurium besylate has successfully concluded its phase IV Clinical Study. The yearlong clinical research project showed no significant differences between Kutai and imported Cisatracurium besylate, and no significant differences for Kutai safety and effectiveness when stored at either room temperature or a lower temperature. The Company estimates that the value of Chinese market is US$120 million and the global market at US$1 billion.
"SNBP conducts research and development through Nanjing Su Ji Biotech Research Development Center and in cooperation with the Medicinal Chemistry Research Institute, Nanjing University. Both are located at Nanjing University in Nanjing. The city has emerged as one of China's major biotech research and development centers. The Company's R&D team of 18 specialists is highly experienced research personnel and medical professionals."
To read the entire report visit: http://www.stockpreacher.com/n/SNBP
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.